All
Cutaneous T-cell lymphoma: Poised for a new treatment paradigm
January 16th 2015Researchers are aiming to better understand the molecular signaling pathways and the immune microenvironment of cutaneous T-cell lymphoma. The use of targeted or mechanism-based therapies may lead to better-understood combinations, higher response rates and better survival.
Takeaway: Considering alternatives
January 15th 2015Dermatology Times editorial advisor, Elaine Siegfried, M.D., talks with Peter Lio, M.D., assistant professor of clinical dermatology and pediatrics at Northwestern University’s Feinberg School of Medicine, and private practice, Dermatology and Aesthetics of Wicker Park, Wicker Park, Chicago, about his interest in alternative medicine and the legitimacy and usefulness of certain techniques and therapies.
Partner Content: E-Mazing Medical Marketing Minute on embracing technology to build practice
January 14th 2015Jacob Boeckmann, M.D., of Facial Aesthetic Concepts in Orange County, Calif., discusses the value of high quality web content to inform and educate both new and existing patients and the value of embracing the benefits of social technology.
Gigapixel camera has eye for melanoma
January 12th 2015Whole-body photographic camera developed out of U.S. military surveillance technology may have applications in dermatology. Dermatologists could one day use the camera to take whole-body images in high-risk patients; then, let a computer do the work of analyzing lesions that need attention.
Wearable technology meets dermatology
January 5th 2015Imagine wearing electronics powerful enough to transdermally measure things like hydration, electrophysiological activity and pulse and cerebral oximetry. But the technology is so thin, breathable, soft and malleable, that you don’t notice it on your skin. It can be on your eyelid, on your lips, over hair. It seamlessly does its job while you live your life without constraint.
FDA accelerates approval of melanoma drug
January 2nd 2015The Food and Drug Administration has granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma and for patients whose disease has progressed following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.
Study shows hair removal’s impact on amputees’ wellbeing
January 2nd 2015Nathanial Miletta, M.D., an Army captain stationed at Walter Reed National Military Medical Center, Bethesda, Md., and his colleagues set out to assess subjective changes, including how dermatologic conditions - such as infection, abcesses, itching, pain, irritation, pulling of leg hair - at the joint interface affect quality of life and whether laser hair removal can help.
FDA Approves Ivermectin 1% Cream for Rosacea
January 2nd 2015Lead author and a Galderma consultant dermatologist Linda Stein Gold, M.D. writes to Dermatology Times that results from Soolantra (ivermectin) Cream, 1% were seen in clinical studies as early as week two, with continuous improvement in patients with inflammatory lesions of rosacea.
Important gaps in dermatology research
December 22nd 2014Kevin D. Cooper, M.D., professor and chair of dermatology at Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, and Steven R. Feldman, M.D., Ph.D., professor of dermatology, Wake Forest University School of Medicine, Winston-Salem, N.C., weigh in on important gaps in dermatology research today.
Diagnosing, managing aBCC in elderly patients
December 17th 2014Advanced BCC may be more common in elderly patients but many cannot tolerate surgery or radiation. Many elderly patients have comorbidities and limitations that limit therapeutic options for aBCC. Vismodegib and other medications that are under study are novel options to help manage their aBCC.
Acquisition breathes new life into Allergan’s R&D efforts
December 16th 2014The recently announced acquisition of Allergan Inc. by Actavis means the Irvine, Calif.-based maker of Botox will no longer be the target of a hostile takeover by Canadian firm Valeant Pharmaceuticals-which in turn means Allergan’s research-and-development programs will continue unabated.